



Coronavirus Disease 2019 (COVID-19)




Ten Clinical Tips on COVID-19 for Healthcare Providers Involved in Patient Care


Updated Sept. 16, 2020

[Print](#)

Treatment and Prophylaxis

1. The National Institutes of Health has developed [guidance on treatment](#) , which will be regularly updated as new evidence on the safety and efficacy of drugs and therapeutics emerges from clinical trials and research publications.
2. There is currently no FDA-approved post-exposure prophylaxis for people who may have been exposed to SARS-CoV-2.

Symptoms and Diagnosis

3. Non-respiratory [symptoms](#) of COVID-19 – such as gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea), or neurologic symptoms (e.g., anosmia, ageusia, headache), or fatigue or body and muscle aches – may appear before fever and lower respiratory tract symptoms (e.g., cough and shortness of breath).
4. [Children](#) with COVID-19 may have fewer symptoms than adults. Although most children with COVID-19 have not had severe illness, clinicians should maintain a high index of suspicion for SARS-CoV-2 infection in children, particularly infants and children with underlying medical conditions. CDC is investigating [multisystem inflammatory syndrome in children](#), a rare but serious complication associated with COVID-19. CDC recommends monitoring children for worsening of COVID-19 illness.
5. [CT scans](#)  should not be used to screen for COVID-19 or as a first-line test to diagnose COVID-19. CT scans should be used sparingly and reserved for hospitalized, symptomatic patients with specific clinical indications for CT scans.

Ten Clinical Tips on COVID-19 for Healthcare Providers Involved in Patient Care

Revised 9/16/2020. <https://www.cdc.gov/media/releases/2020/s100916-covid-19-clinical.html>

Treatment and Prophylaxis

1. The National Institutes of Health has developed [guidance on treatment](#) , which will be regularly updated as new evidence on the safety and efficacy of drugs and therapeutics emerges from clinical trials and research publications.
2. There is currently no FDA-approved post-exposure prophylaxis for people who may have been exposed to COVID-19 [https://www.cdc.gov/coronavirus/2019-ncov/faq.html](#).

Symptoms and Diagnosis

3. **Non-respiratory symptoms** [https://www.cdc.gov/coronavirus/2019-ncov/clinical-guidance-management.html](#) of COVID-19, such as gastrointestinal (e.g., nausea, diarrhea, or vomiting), symptoms (e.g., anosmia, ageusia, headache), or fatigue or body and muscle aches – may appear before fever and lower respiratory tract symptoms (e.g., cough and shortness of breath).
4. **Children** [https://www.cdc.gov/coronavirus/2019-ncov/children.html](#) with COVID-19 may have fewer and cough of symptoms than adults. Although most children with COVID-19 have not had severe illness, clinicians should maintain a high index of suspicion for SARS-CoV-2 infection in children, particularly infants and children with underlying medical conditions. CDC is investigating [multisystem inflammatory syndrome in children](#), a rare but serious complication associated with COVID-19. CDC recommends monitoring children for worsening of COVID-19 illness.
5. **CT scans** [https://www.cdc.gov/coronavirus/2019-ncov/clinical-guidance-management.html](#) should not be used to screen for COVID-19 or as a first-line test to diagnose COVID-19. CT scans should be used sparingly and reserved for hospitalized, symptomatic patients with specific clinical indications for CT scans.

Coinfections

6. Patients can be infected with more than one virus at the same time. **Coinfections with other respiratory viruses** [https://www.cdc.gov/coronavirus/2019-ncov/clinical-guidance-management.html](#) in people with COVID-19 have been reported. Therefore, identifying infection with one respiratory virus does not exclude SARS-CoV-2 virus infection.
7. Several patients with COVID-19 have been reported presenting with **documented community-acquired bacterial pneumonia** [https://www.cdc.gov/coronavirus/2019-ncov/clinical-guidance-management.html](#). Clinicians to administer antibiotics to COVID-19 patients should be based on the likelihood of bacterial infection, community-acquired or hospital-acquired, illness severity, and antimicrobial stewardship issues [https://www.cdc.gov/coronavirus/2019-ncov/clinical-guidance-management.html](#).



Severe illness

8. Clinicians should be aware of the potential for some patients to **rapidly deteriorate** [https://www.cdc.gov/coronavirus/2019-ncov/clinical-guidance-management.html](#) one week after illness onset.
9. The median **time to acute respiratory distress syndrome (ARDS)** ranges from 8 to 12 days [https://www.cdc.gov/coronavirus/2019-ncov/clinical-guidance-management.html](#).
10. Lymphopenia, leukopenia, elevated serum alanine aminotransferase and aspartate aminotransferase levels, elevated lactate dehydrogenase, high CRP and high ferritin levels may be associated with **greater illness severity** [https://www.cdc.gov/coronavirus/2019-ncov/clinical-guidance-management.html](#).

[cdc.gov/coronavirus](#)

[Download the fact sheet](#) 

Co-Infections

6. Patients infected with SARS-CoV-2 (the virus that causes COVID-19) can have another viral (such as influenza), bacterial, or fungal infection at the same time. During widespread cocirculation of SARS-CoV-2 and influenza, clinicians should consider testing patients with compatible symptoms for both viruses.
7. Several patients with COVID-19 have been reported presenting with concurrent community-acquired bacterial [pneumonia](#)  . Decisions to administer antibiotics to COVID-19 patients should be based on the likelihood of bacterial infection (community-associated or healthcare-associated), illness severity, and [current clinical practice guidelines](#)  .

Severe Illness

8. Clinicians should be aware of the potential for some patients to rapidly [deteriorate](#) 1 week after illness onset.
9. The median time to acute respiratory distress syndrome ([ARDS](#)) ranges from 8 to 12 days.
10. Lymphopenia, neutrophilia, elevated serum alanine aminotransferase and aspartate aminotransferase levels, elevated lactate dehydrogenase, high CRP, and high ferritin levels may be associated with greater [illness severity](#).

Last Updated Sept. 16, 2020

Content source: [National Center for Immunization and Respiratory Diseases \(NCIRD\)](#), [Division of Viral Diseases](#)